Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-cash Items (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Non-cash Items for 7 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 15.84% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, up 15.84% year-over-year, with the annual reading at $4.7 million for FY2025, 15.84% up from the prior year.
  • Non-cash Items hit $4.7 million in Q4 2025 for Eton Pharmaceuticals, up from $4.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $8.8 million in Q1 2021 to a low of $1.5 million in Q2 2021.
  • Historically, Non-cash Items has averaged $3.6 million across 5 years, with a median of $3.5 million in 2022.
  • Biggest YoY gain for Non-cash Items was 981.51% in 2021; the steepest drop was 76.48% in 2021.
  • Year by year, Non-cash Items stood at $2.7 million in 2021, then grew by 2.9% to $2.8 million in 2022, then grew by 21.88% to $3.4 million in 2023, then increased by 18.95% to $4.0 million in 2024, then grew by 15.84% to $4.7 million in 2025.
  • Business Quant data shows Non-cash Items for ETON at $4.7 million in Q4 2025, $4.4 million in Q3 2025, and $4.4 million in Q2 2025.